Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800237 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
A Phase 2 study of Performance Anxiety, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 15
- Study locations
NCT04800237 is a Phase 2 study of Performance Anxiety that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 230 participants. The trial reports 15 study locations across 10 states.
The verdict
NCT04800237, a Phase 2 study of Performance Anxiety, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VQW-765
Study Locations (15)
California
- Vanda Investigational Site - Beverly Hills
- Vanda Investigational Site - Garden Grove
- Vanda Investigational Site - San Jose
- Vanda Investigational Site - Torrance
Massachusetts
- Vanda Investigational Site - Boston
- Vanda Investigational Site - North Dartmouth
New York
- Vanda Investigational Site - New York
- Vanda Investigational Site - Staten Island
Arizona
- Vanda Investigational Site - Tempe
Florida
- Vanda Investigational Site - Orlando
Nevada
- Vanda Investigational Site - Las Vegas
New Jersey
- Vanda Investigational Site - Berlin
North Carolina
- Vanda Investigational Site - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2022-08-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04800237
The ClinicalTrials.gov registry entry for NCT04800237 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Performance Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04800237 reports 15 study locations spanning 10 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04800237 about?
NCT04800237 is a clinical study titled "Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety". This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.
What is the current status of trial NCT04800237?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2021-02-23. Estimated completion is 2022-08-02.
What conditions does trial NCT04800237 study?
This clinical trial studies the following conditions: Performance Anxiety.
What interventions are being tested in trial NCT04800237?
The interventions under investigation include: Placebo (DRUG), VQW-765 (DRUG).
Who is sponsoring clinical trial NCT04800237?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04800237 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Performance Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.